Tag Archives: SRPT

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Incyte (NASDAQ: INCY) and Lexicon Pharmaceuticals (NASDAQ: LXRX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Incyte (INCY – Research Report) and Lexicon Pharmaceuticals (LXRX – Research Report). Sarepta Therapeutics (SRPT) Credit Suisse

Nomura Remains a Buy on Sarepta Therapeutics (SRPT)

Nomura analyst Christopher Marai maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) on May 15 and set a price target of $230.00. The company’s shares closed last Friday at $141.25. According to TipRanks.com, Marai is a 4-star

A Director at Sarepta Therapeutics (NASDAQ: SRPT) is Selling Shares

Yesterday, a Director at Sarepta Therapeutics (SRPT – Research Report), Richard Barry, sold shares of SRPT for $4.24M. Following Richard Barry’s last SRPT Sell transaction on September 16, 2019, the stock climbed by 54.2%. This is Barry’s first Sell trade

Mizuho Securities Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $183.00. The company’s shares closed last Friday at $139.34. According to TipRanks.com, Yang has currently 0 stars

H.C. Wainwright Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)

H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $260.00. The company’s shares closed last Thursday at $127.05. According to TipRanks.com, Chattopadhyay is a 5-star analyst

Sarepta Therapeutics (SRPT) Gets a Buy Rating from Credit Suisse

Credit Suisse analyst Martin Auster maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) yesterday and set a price target of $185.00. The company’s shares closed last Thursday at $126.25. According to TipRanks.com, Auster is a 5-star analyst